TRI Heart LLC

Presenter: Hobey Tam Advisor: Narendra Vyavahare, Ph.D.

300,000+ heart valve replacements annually.

$1.25 BIL market space.

7% CAGR in US. 11 15% CAGR in emerging markets.

Market Dynamics

Our Value Proposition

Glutaraldehyde valves (80% Market Share) Calcification + Structural degradation

Mechanical valves (20% Market Share)

Anticoagulation medication

We have provisionally patented a biomaterial fabrication method for use in heart valve replacements.

TRI valves

Resistant to calcification + structural degradation No anticoagulants req.

The Business Model and Commercialization Strategy.

Not feasible to start and grow enterprise selling heart valves (FDA/CE, established competitors).

TRI Heart, LLC functions to derisk the novel fabrication protocol, TRI.
Core Strategy 50/50 split between R&D and business channel development. Act as pipeline company like in pharma Core values Stay small, agile remain pivotal to have unparalleled pace of bootstrap R&D Exit Strategy Acquisition by a large producer of biomaterials or valves ($30 50MIL)

TRI Heart LLC

Trying harder to give you the solutions of tomorrow, today.